Repurposing Nitazoxanide for Potential Treatment of Rare Disease Lymphangioleiomyomatosis
Open Access
- 30 September 2024
- journal article
- research article
- Published by MDPI AG in Biomolecules
- Vol. 14 (10) , 1236
Abstract
Lymphangioleiomyomatosis (LAM) is a rare genetic lung disease. Unfortunately, treatment with the mTORC1 inhibitor Rapamycin only slows disease progression, and incomplete responses are common. Thus, there remains an urgent need to identify new targets for the development of curative LAM treatments. Nitazoxanide (NTZ) is an orally bioavailable antiprotozoal small molecule drug approved for the treatment of diarrhea caused by Giardia lamblia or Cryptosporidium parvum in children and adults, with a demonstrated mTORC1 inhibitory effect in several human cell lines. NTZ’s excellent safety profile characterized by its more than 20 years of clinical use makes it a promising candidate for repurposing. Our rationale for this study was to further investigate NTZ’s effect using in vitro and in vivo LAM models and to elucidate the underlying molecular mechanism beyond mTORC1 inhibition. For this purpose, we investigated cell proliferation, cell viability, and changes in protein phosphorylation and expression in primary human cell cultures derived from LAM lung samples before translating our results into a syngeneic mouse model utilizing Tsc2-null cells. NTZ reduced cell growth for all tested cell lines at a dose of about 30 µM. Lower doses than that had no effect on cell viability, but doses above 45 µM lowered the viability by about 10 to 15% compared to control. Interestingly, our western blot revealed no inhibition of mTORC1 and only a mild effect on active ß-Catenin. Instead, NTZ had a pronounced effect on reducing pAkt. In the mouse model, prophylactic NTZ treatment via the intraperitoneal and oral routes had some effects on reducing lung lesions and improving body weight retention, but the results remain inconclusive.Keywords
Funding Information
- National Institutes of Health National Heart, Lung, and Blood Institute (1R41HL156767-01A1)
This publication has 37 references indexed in Scilit:
- Lymphangioleiomyomatosis and pregnancy: a mini-reviewArchives of Gynecology and Obstetrics, 2024
- Safety and Efficacy of Combined Resveratrol and Sirolimus in LymphangioleiomyomatosisChest, 2023
- Synthetic antiprotozoal thiazolide drug induced apoptosis in colorectal cancer cells: implications of IL-6/JAK2/STAT3 and p53/caspases-dependent signaling pathways based on molecular docking and in vitro studyMolecular and Cellular Biochemistry, 2020
- Tizoxanide induces autophagy by inhibiting PI3K/Akt/mTOR pathway in RAW264.7 macrophage cellsArchives of Pharmacal Research, 2020
- mTOR Signaling in Growth, Metabolism, and DiseaseCell, 2017
- Nitazoxanide: A first-in-class broad-spectrum antiviral agentAntiviral Research, 2014
- Folliculin Controls Lung Alveolar Enlargement and Epithelial Cell Survival through E-Cadherin, LKB1, and AMPKCell Reports, 2014
- Rapamycin: One Drug, Many EffectsCell Metabolism, 2014
- Cell Viability Analysis Using Trypan Blue: Manual and Automated Methods2011
- Lymphangioleiomyomatosis: A reviewEuropean Journal of Internal Medicine, 2008